The inflationary cap on list price growth will impact drug makers, which have already seen their net prices stagnate in recent years and even enter negative territory. It will also lower Medicare beneficiaries' out-of-pocket spend and affect price negotiations between PBMs and drug makers.
Subscribe to:
Post Comments (Atom)
< + > Sherpas Healthcare Solutions Relieves the Burden of Release of Information Requests
Health care organizations still have to handle thousands of patient record requests manually. In addition to individual records requested by...
No comments:
Post a Comment